Abstract
Introduction

Lupus nephritis is characterized by loss of B-cell tolerance to selfantigen and the presence of abnormally activated circulating B cells
, contributing to tissue damage by secreting autoantibodies [2] . In disease models, activated autoreactive B cells can also drive the loss of tolerance in the T-cell compartment [3] . [4] [5] [6] [7] . Transgenic mice overexpressing BAFF develop symptoms characteristic of systemic lupus erythematosus (SLE), with high levels of rheumatoid factors, circulating immune complexes, anti-DNA autoantibodies and immunoglobulin deposition in the kidneys. The animals eventually succumb to an immune complexmediated, lupus-like nephritis [8] [9] [10] [11] . The levels of BAFF are also elevated in the serum of patients with SLE, correlated with circulating levels of anti-dsDNA antibodies and with clinical disease activity [12] [13] [14] [15] . Thus, inhibition of BAFF signalling is a potential therapeutic option for treating lupus nephritis. [9, 17] . [19] . Although BAFF-R-Ig seems more specific, unlike human BAFF-R, mouse BAFF-R can also weakly bind to mouse APRIL [20] 
B-cellactivating factor (BAFF, also called TALL-1, zTNF4, BlyS and TNFSF13b) is a member of the TNF superfamily that is essential for B-cell survival, proliferation and immunoglobulin secretion
. Even in the absence of T-cell help, BAFF-transgenic mice that were completely deficient in T cells still develop an SLE-like disease, indicating a critical role of BAFF in B-cell autoimmunity
In addition to interacting with BAFF receptor (BAFF-R, BR3, TNFRSF13C), BAFF also binds to two other receptors. One is transmembrane activator and calcium-modulator and cyclophilin ligand (CAML) interactor (TACI, TNFRSF13B), and the other is B-cell maturation antigen (BCMA, TNFRSF17). Compared with BAFF-R, these two receptors have more restricted functions: TACI controls T-cell-independent B-cell antibody response, isotype switching and B-cell homeostasis, whereas BCMA supports the survival of bone marrow plasma cells (for review, see reference [16]). Of the three receptors for BAFF, only BAFF-R is specific and the primary receptor for transmitting the BAFF-dependent B-cell survival signal, whereas TACI and BCMA also bind to the related ligand APRIL (a proliferation-inducing ligand, TNFSF13)
Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice
Western blot of BAFF-R-IgG4mut fusion protein
BAFF-R-IgG4mut fusion protein was expressed and purified by Protein A affinity column chromatography as described previously [23] . Purity 
Treatment of mice with BAFF-R-IgG4mut fusion protein
Eight weeks old BXSB male mice were randomly divided into three groups (15 
Assessment of nephritis
For monitoring the development of nephritis, proteinuria was measured as described previously [25] [28] .
Statistical analysis
Log-rank and Student's t-tests were used. Methods were noted in figure legends. Values of P Ͻ 0.05 were considered significant. (Fig. 1A) . The authenticity of the BAFF-R moiety was confirmed by Western blot (Fig. 1B) 
Results
BAFF-R-IgG4mut fusion protein blocks BAFF activity in vitro
BAFF-R-IgG4mut prevents the development of lupus-like nephritis
To assess the effects of BAFF-R-IgG4mut on the development of lupus-like nephritis, we started the treatment of BXSB mice at 8 weeks of age before serum levels of BAFF were elevated. Proteinuria (Ͼ100 mg/dl) was first detected in the control mice (PBS or IgG) at 9 weeks of age and became prominent at 12 weeks of age (Fig. 3A). At the cessation of treatment (15 weeks of age), 100% of the mice treated with PBS or IgG4 developed renal disease with proteinuria Ͼ100 mg/dl. Although 50% of the mice treated with BAFF-R-IgGmut developed proteinuria at 15 weeks of age, the disease course was significantly delayed (P Ͻ 0.01). As the hallmark of lupus is the development of anti-dsDNA autoantibodies, we measured by ELISA the levels of serum anti-dsDNA IgG in BXSB mice after different treatments. The results showed that BXSB mice treated with PBS or IgG4 possessed highly elevated levels of serum anti-dsDNA IgG, and there was an obvious
Fig. 1 Characterization of BAFF-RIgG4mut fusion protein. (A) SDS-PAGE analysis. A and B both are loaded with purified BAFF-R-IgG4mut. (B) Western blot analysis with anti-BAFF-R mAb. 1, negative control; 2, BAFF-R-IgG4mut fusion protein; M, molecular weight marker. (C) In vitro bioactivity assay. Purified mouse splenic B cells were stimulated with 5 g/ml (left side) or 10 g/ml (right side) of anti-IgM in the presence of 2 ng/ml of BAFF and indicated doses of BAFF-R-IgG4mut fusion protein. B-cell proliferation after 3 days was measured by 3 H-thymidine incorporation in triplicates. B-cell thymidine incorporation by anti-IgM stimulation alone was labelled as a flat line in each side. BAFF-R-IgG4mut alone did not stimulate B-cell proliferation (data not shown). trend of increase in antibody titres with age. The levels of antidsDNA IgG were suppressed in the mice 4 weeks after the initial treatment with BAFF-R-IgG4mut and were maintained at 15 weeks of age compared with PBS or IgG treatment alone (P ϭ 0.035) (Fig. 3B). Animals treated with BAFF-R-IgG4mut had 100% survival at 30 weeks of age compared with 0% survival in the control group (P Ͻ 0.01) (Fig. 3C). Although all animals in BAFF-RIgG4mut-treated group eventually died of disease, this may be as a result of the neutralization of this human fusion protein by murine anti-human antibody.
Histological verification of the beneficial effects of BAFF-R-IgG4mut
The (Fig. 4C) , the intensity of such IgG deposition was clearly inhibited in mice treated with BAFF-R-IgG4mut (Fig. 4D) . In semi-quantitative analyses, BAFF-R-IgG4mut treatment showed the most significant inhibition on glomerular hypercellularity, tubular interstitial inflammatory cell infiltration and IgG deposition, compared with treatment with PBS or IgG (Fig. 4E-G (Fig. 5A) . [29] [30] [31] [32] . In this study, we used hBAFF-R-Ig instead of mBAFFR-Ig to specifically block BAFF signalling in mice. This is because mouse BAFF-R weakly binds to mouse APRIL, and hence high experimental doses of recombinant soluble mouse BAFF-R-Ig may inhibit mouse APRIL in addition to BAFF [20] . We used BXSB mice, a well-characterized mouse model that spontaneously develops an autoimmune syndrome similar to human SLE, and is characterized by hypergammaglobulinemia, autoantibody production and the development of fatal glomerulonephritis. Positive serology to self-Ags (dsDNA, ssDNA, erythrocytes and platelets) and immune complex-mediated glomerulonephritis is the hallmark of disease in BXSB mice. mice, leading to end-stage renal disease and 70% mortality by 40 weeks of age [33, 34] .
improvement of nephritis by BAFF-R-IgG4mut treatment was verified by histological examination of glomerular hypercellularity, tubular interstitial inflammatory cell infiltration and IgG deposition in renal tissue sections from mice that underwent different treatments. At 15 weeks of age, renal sections from PBS or IgG-treated mice showed mesangial hypercellularity, in conjunction with tubular interstitial inflammatory cell infiltration (Fig. 4A). The above pathological changes were diminished in BAFF-R-IgG4mut-treated mice (Fig. 4B). While there was strong deposition of IgG to glomeruli in PBS or IgG4-treated mice
Effects of BAFF-R-IgG4mut on lymphocyte composition
To study the potential mechanisms contributing to the suppression of disease in BAFF-R-IgG4mut-treated animals, we determined the percentage of B cells (B220
ϩ CD5 Ϫ ) and T cells (CD3 ϩ CD4 Ϫ CD8 ϩ , CD3 ϩ CD4 ϩ CD8 Ϫ
) by flow cytometry at 10, 12 and 15 weeks of age. At 12 weeks of age (4 weeks after treatment), there was already a significant decrease of the percentage of B cells in the peripheral blood and spleen in animals treated with BAFF-R-IgG4mut, compared with control animals
To show this effect is B-cell specific, we used the B220
Ϫ CD5 Ϫ
non-T, non-B cell population as an internal calibrator, and calculated the ratios of B or T cells versus this calibrating population. We found that starting from 12 weeks of age, BXSB mice had increased B-cell population in both the spleen and the peripheral blood. Treatment with BAFF-R-IgG4mut fusion protein significantly suppressed B-cell expansion, while having no effect on T cells (Fig. 5B). These results indicate a role for BAFF in maintaining peripheral B-cell populations and blocking BAFF:BAFF-R has a beneficial effect on inhibiting B-cell hyperplasia in murine lupus.
Discussion
BAFF-R is expressed on T cells and a wide range of B-cell subsets, including immature, transitional, mature, memory and germinal centre B cells, as well as on plasma cells
The 
